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Combination Antifungal Therapy Experience at an
Academic Health System
David R. Ha 1,2, Nina Haste 2, Charles James 2,
Katherine Medley 2, Randy Taplitz 3. 1 Clinical and
Administrative Sciences, Keck Graduate Institute School of
Pharmacy, Claremont, CA; 2 Pharmacy, UC San Diego
Healthsystem, San Diego, CA; 3Medicine, University of
California, San Diego, La Jolla, CA
Purpose: Invasive fungal infections are becoming increas-
ingly prevalent, particularly in the immunocompromised
population. The development of new antifungal agents with
novel mechanisms of action has sparked interest in
combination antifungal therapies. This study seeks to
characterize combination antifungal use at a large academic
health system.
Methods: We conducted a retrospective observational study
of adult inpatients with the intent of characterizing
combination systemic antifungal utilization between the
dates of July 1, 2012 and June 30, 2013. Combination
antifungal therapy was deﬁned as administration of two or
more target systemic antifungals (liposomal amphotericin B,
ﬂuconazole, voriconazole, posaconazole, micafungin or
terbinaﬁne) for ﬁve or more days.
Results: Twenty nine patients received combination
antifungal therapy and 36 unique treatment courses were
identiﬁed. Ten of the 29 patients (35%) were BMT patients.
Pneumoniawas themost common disease indication (20/29;
69%). Unknown was the most common organism indication
overall (11/29; 38%) and within the BMT patient population
(6/10; 60%). Among the 36 unique treatment courses the
most common combination therapy by drug class was an
azole and an echinocandin (53%; 19/36) followed by a
polyene and an azole (31%; 11/36).
Conclusion: A signiﬁcant proportion of the study popula-
tion both overall (35%) and among BMT patients (60%)
received combination antifungal therapy with no identiﬁed
infecting fungal organism. There is no data to support such
a practice. However, in the setting of severe invasive fungal
infections, particularly in immunocompromised hosts, us-
ing additional antifungal agents may seem less risk-prone
than invasive diagnostics like tissue biopsy. These ﬁndings
suggest that earlier diagnostic methods including tissue
biopsy are warranted to avoid unnecessary use of combi-
nation antifungal therapy when no pathogen has been
identiﬁed.348
Effect of Linezolid Administration on Myeloid
Engraftment after Allogeneic Hematopoietic Stem Cell
Transplantation
Risa Hashida, Takehiko Mori, Jun Kato, Sumiko Kohashi,
Shinichiro Okamoto. Division of Hematology, Keio University
School of Medicine, Tokyo, Japan
Background: Linezolid is effective against drug-resistant
Gram-positive bacteria, and has been widely used for the
treatment of various infectious diseases due to such bacteria.
Although linezolid has a favorable safety proﬁle, myelosup-
pression is one of its clinically important toxicities.
Myelosuppression due to linezolid has not beensystematically evaluated in the setting of hematopoietic stem
cell transplantation (HSCT). Therefore, effect of linezolid
administration on the myeloid engraftment after allogeneic
HSCT was retrospectively evaluated.
Patients and Methods: Patients in whom intravenous or
oral linezolid (1200 mg/day) administration was initiated
before myeloid engraftment following allogeneic HSCT
and continued for 5 days or longer were selected from
the institutional database. The patient characteristics,
duration of linezolid treatment, and myeloid engraftment
were retrospectively evaluated by using the medical
records.
Results: Fifteen patients were evaluable and enrolled into
the analysis. All patients were male, and median age at
transplant was 50 years (range, 21e60). Underlying diseases
were acute leukemia in 11 patients, myelodysplastic
syndrome in 2, and myeloproliferative neoplasm and
malignant lymphoma each in 1. All but 1 received myeloa-
blative conditioning. Stem cell sources were bone marrow
from related or unrelated donor in 10 patients, cord blood in
3, and peripheral blood stem cell (PBSC) in 2. Linezolid was
initiated at a median of 12.5 days after HSCT (range, -3e20),
whose median duration of treatment was 14 days (range,
5e20). Although all patients achieved myeloid engraftment
(absolute neutrophil exceeding 0.5 x 109/L), the median day
of engraftment was 22.5 days after HSCT (range, 12e33).
Japanese national registry data showed that the median days
of myeloid engraftment were 12 days and 14 days after
allogeneic PBSCT and BMT, respectively (Nagafuji K, et al. Int J
Hematol 2010). In 8 (53%) of 15 patients, myeloid engraft-
ment was achieved later than 21 days after engraftment.
Conclusion: Although myeloid engraftment was achieved,
the engraftment was considered delayed in patients who
received linezolid early after allogeneic HSCT. Although the
number of subjects evaluated was small, these results
suggest that linezolid could have a potential to delay
neutrophil recovery, and should be carefully used after
allogeneic HSCT.349
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Background: Posaconazole (PCZ) delayed-release (DR)
tablets were FDA approved in late 2013 for prophylaxis of
invasive fungal infections (IFI). In 3 clinical studies leading to
approval, PCZ DR exhibited signiﬁcant pharmacokinetic
advantages over oral suspension (OS), largely due to
improved absorption. Historically, subtherapeutic PCZ OS
levels were linked with breakthrough IFI. We aim to evaluate
PCZ DR serum levels in the bone marrow transplant (BMT)
population and link levels to IFI breakthrough prevention
and treatment.
Methods: After approval by Pharmacy and Therapeutics, PCZ
levels were routinely obtained in BMT patients18 years old
started on PCZ DR. A retrospective chart review was
performed between January 1 and June 30, 2014. Baseline
demographics, PCZ dose and levels, as well as patient speciﬁc
factors with the potential to affect levels and development of
IFIs were collected.
Mean±SD Median Range
Mean daily calorie
intake (kcal)
Total 1530.4452.1 1516.0 253.0e2697.0
Kcal/kg 18.86.3 18.5 3.2e38.5
Mean daily protein
intake (grams)
Total 52.720.0 50.7 4.5e109.4
g/kg 0.650.26 0.63 0.06-1.48
Time to neutrophil
engraftment (days)
15.12.5 15.0 10-23
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265S252Results: Steady state ( 5 days maintenance PCZ)
concentrations (n ¼ 34) were evaluated in 24 BMT patients
(median age 62 years (22e78), 45% female), with 20 treated
prophylactically (maintenance 300 mg daily), and 4 dosed
with treatment intent (400 mg daily with 1 patient adjusted
to 300 mg after a level of 4.3). An average weight-based dose
of 4.13 mg/kg yielded average levels of 1.53 mcg/mL. Ranges
of 3 to 5 mg/kg (16/24 patients) led to average levels of 1.37
mcg/mL (0.5 e 2.5). Higher levels (2.32 mcg/mL (0.8e4.3))
were seen in doses >5 mg/kg (6/24 patients). Doses
< 3mg/kg yielded low levels (0.4) (2 patients). Of 20 patients
on prophylaxis, 1 developed a probable IFI with a therapeutic
PCZ level. Of 4 patients on treatment, 2 improved and 2
died (both of progressive AML), all with therapeutic/
supratherapeutic levels.
Conclusion: Therapeutic drug monitoring has previously
been used for PCZ treatment and prophylaxis. Levels  0.7
mcg/mL in prior OS studies were associated with
successful prophylaxis vs. IFI breakthrough. In this adult BMT
population, levels exceeded this threshold, and were
consistent with treatment doses or higher. We postulate that
weight-based dosing may give adequate prophylactic levels
on lower total mg doses while offering beneﬁts of reduced
cost and avoided toxicities. Further associations of PCZ levels
with efﬁcacy and adverse events are warranted.350
A Study of Dietary Intake and the Relationship to
Neutrophil Engraftment Among Outpatient
Hematopoietic Stem Cell Transplant Patients with
Multiple Myeloma
Joy R. Heimgartner 1, Shahrukh Hashmi 2, Francis Buadi 2,
Joan Vruwink 1, William Hogan 2. 1 Endocrinology, Diabetes &
Nutrition, Mayo Clinic, Rochester, MN; 2Division of
Hematology, Mayo Clinic, Rochester, MN
Introduction: At Mayo Clinic (MN) autologous hematopoi-
etic stem cell transplants (HSCT) for Multiple Myeloma (MM)
are performed on an outpatient basis and patients consume
only an oral ad libitum diet. Current literature suggests that
calorie and protein needs following HSCT exceed basal
requirements, despite lack of evidence that this improves
outcomes.
Objectives: To describe the calorie and protein intake of
MM patients receiving outpatient autologous HSCT, and
explore relationships between oral intake and neutrophil
engraftment.
Methods: Intake information from patient food records were
reviewed retrospectively for adult MMpatients who received
auto HSCT from 2010 through 2012. Descriptive statistics
were used to describe the demographic and clinical
characteristics. Pearson’s correlations were utilized to
explore relationships between calorie and protein intake and
engraftment.
Results: n¼230 was predominantly male (56.1%) with mean
age of 60.6 years (range 35-75 years). At the time of trans-
plant, 77.8% had a BMI classiﬁed as either overweight or
obese. The mean calorie intake of the sample was
1530.4452.1 per day (18.86.3 kcal/kg/day) and mean
protein intake of 52.720.0 grams per day (0.650.26 g/kg/
day). Mean time to neutrophil engraftment was 15.12.5
days (range 10-23 days). There were statistically signiﬁcant
weak positive correlations between calorie (r¼+0.187,
p¼0.004) and protein intake (r¼+0.199, p¼0.002) and
engraftment, but not clinically meaningful differences given
many other variables affecting engraftment.Conclusions: Compared to the general population, study
subjects had a higher prevalence of overweight or obesity. A
majority of patients did not meet estimated basal energy or
protein requirements; however there was no correlation
between calorie or protein intake and engraftment timing
that could be considered clinically relevant. Calorie & Protein
Intake and Timing of Neutrophil Engraftment in patients was
considered.
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Introduction: Bacterial infections are a serious complication
following allogeneic hematopoietic stem cell transplantation
(HSCT). There are limited data on the incidence and risk
factors in pediatric recipients.
Patients and Methods: We retrospectively reviewed medi-
cal records of all pediatric patients who received allogeneic
HSCT between January 2008 and April 2014 at King Hussein
Cancer Center (KHCC) in Jordan. All bacterial infections
including blood and non-blood related were included. No
prophylaxis antibiotic was routinely used. Piperacillin and
Amikacin were used empirically for fever episodes during
the ﬁrst 100 days following HSCT.
Results: A total of 200 pediatric patients were identiﬁed,
with median age of 9 year (2 month-27 year). Sixty percent
(n¼119) were males. One hundred and nineteen patients
(60%) had non-malignant diseases. Peripheral blood (PB) was
the stem cell source in 110 (55%), 69 (34.5%) bone marrow
and 21 (10.5%) cord blood. Sixty nine percent received
myeloablative conditioning (n¼137), 26% reduced intensity
(n¼52) and 5% no conditioning regimen (n¼11). One hun-
dred eighty two (91%) were matched-related (140 were HLA
identical siblings and 42 were other family donors). A total of
151 bacterial infections were documented in 77 patients
(39%). Gram positive (GP) isolates were slightly more prev-
alent (52%) than gram negative (GN) (48%). One hundred and
ﬁve episodes were isolated from blood stream (70%), 38 from
skin, nasal and throat swabs (24.7%), and 8 from urine (5.3%).
The GP isolates were more prevalent from blood stream,
while GN were the prevalent ones at other sites (p¼0.001).
Coagulase negative staphylococcus (CONS) was the most
predominant isolate in all sites (33%), followed by Escher-
ichia coli (15%). Most of the bacterial infection episodes (60%)
occurred prior to neutrophil engraftment. Eight deaths
